Ann Pediatr Endocrinol Metab.  2025 Apr;30(2):77-85. 10.6065/apem.2448122.061.

Phenotypic spectrum and long-term outcomes of patients with 46,XX disorders of sex development

• Yoon H
• Kim D
• Kim JH
• Yoo HW
• Choi JH

• KMID: 2567362
• DOI: http://doi.org/10.6065/apem.2448122.061

Abstract

Purpose
46,XX disorders of sex development (DSD) involve atypical genitalia accompanied by a normal female karyotype. This study was performed to investigate the clinical characteristics and long-term outcomes of patients with 46,XX DSD.
Methods
The study included 34 patients with 46,XX DSD who presented with ambiguous genitalia or delayed puberty. Patients with congenital adrenal hyperplasia were excluded. Clinical phenotypes and overall outcomes were analyzed retrospectively.
Results
Age at presentation ranged from birth to 40 years (median, 0.6 years), and the follow-up period ranged from 0.3 to 29.7 years (median, 8.8 years). Twenty patients were assigned female (58.8%). Etiologies included disorders of gonadal development (n=22), exogenous androgen exposure during pregnancy (n=5), association with syndromic disorders or genital anomalies (n=2), and unclassified causes (n=5). Ovotestis was the most frequent gonadal pathology (41.7%). Müllerian duct remnants were usually underdeveloped (52.9%) or absent (23.5%). Spontaneous puberty occurred in 17 of the 21 patients of pubertal age, while 9 patients required sex hormone replacement therapy. Gonadal complications were observed in 4 patients (gonadal tumors [n=3], and spontaneous gonadal rupture [n=1]), and gender dysphoria occurred in 1 patient who was assigned male.
Conclusion
This study described the wide phenotypic spectrum and pubertal outcome of patients with 46,XX DSD. Long-term multidisciplinary monitoring for pubertal development, fertility, gender identity, and gonadal complications is recommended.

Keyword

Ambiguous genitalia; Disorder of sex development; Gonadal dysgenesis; Ovotestis

Figure

• 

  Fig. 1. Etiological classification of patients with 46,XX disorders of sex development (DSD).

• 

  Fig. 2. Pubertal outcomes of the 34 patients included in this study and the hormonal replacement therapies applied. E, estrogen; P, progesterone; T, testosterone; OT-DSD, ovotesticular disorder of sex development.

Reference

References

1. Lee PA, Houk CP, Ahmed SF, Hughes IA. Consensus statement on management of intersex disorders. International consensus conference on intersex. Pediatrics. 2006; 118:e488–500.

2. Lee PA, Nordenstrom A, Houk CP, Ahmed SF, Auchus R, Baratz A, et al. Global disorders of sex development update since 2006: perceptions, approach and care. Horm Res Paediatr. 2016; 85:158–80.

3. Berglund A, Johannsen TH, Stochholm K, Aksglaede L, Fedder J, Viuff MH, et al. Incidence, prevalence, diagnostic delay, morbidity, mortality and socioeconomic status in males with 46,XX disorders of sex development: a nationwide study. Hum Reprod. 2017; 32:1751–60.

4. Chen T, Tian L, Wu F, Xuan X, Ma G, Tang R, et al. Clinical and genetic analysis in males with 46,XX disorders of sex development: a reproductive centre experience of 144 cases. Andrologia. 2019; 51:e13232.

5. Ocal G, Berberoglu M, Siklar Z, Aycan Z, Hacihamdioglu B, Savas Erdeve S, et al. Clinical review of 95 patients with 46,XX disorders of sex development based on the new Chicago classification. J Pediatr Adolesc Gynecol. 2015; 28:6–11.

6. Alkhzouz C, Bucerzan S, Miclaus M, Mirea AM, Miclea D. 46,XX DSD: developmental, clinical and genetic aspects. Diagnostics (Basel). 2021; 11:1379.

7. Barseghyan H, Delot EC, Vilain E. New technologies to uncover the molecular basis of disorders of sex development. Mol Cell Endocrinol. 2018; 468:60–9.

8. Eggers S, Sadedin S, van den Bergen JA, Robevska G, Ohnesorg T, Hewitt J, et al. Disorders of sex development: insights from targeted gene sequencing of a large international patient cohort. Genome Biol. 2016; 17:243.

9. Kim JH, Kang E, Heo SH, Kim GH, Jang JH, Cho EH, et al. Diagnostic yield of targeted gene panel sequencing to identify the genetic etiology of disorders of sex development. Mol Cell Endocrinol. 2017; 444:19–25.

10. Dong Y, Yi Y, Yao H, Yang Z, Hu H, Liu J, et al. Targeted next-generation sequencing identification of mutations in patients with disorders of sex development. BMC Med Genet. 2016; 17:23.

11. Hughes LA, McKay-Bounford K, Webb EA, Dasani P, Clokie S, Chandran H, et al. Next generation sequencing to improve the diagnosis and management of patients with disorders of sex development. Endocr Connect. 2019; 8:100–10.

12. Kim YM, Oh A, Kim KS, Yoo HW, Choi JH. Pubertal outcomes and sex of rearing of patients with ovotesticular disorder of sex development and mixed gonadal dysgenesis. Ann Pediatr Endocrinol Metab. 2019; 24:231–6.

13. Prader A. Genital findings in the female pseudohermaphroditism of the congenital adrenogenital syndrome; morphology, frequency, development and heredity of the different genital forms. Helv Paediatr Acta. 1954; 9:231–48.

14. Ahmed SF, Achermann JC, Arlt W, Balen A, Conway G, Edwards Z, et al. Society for endocrinology UK guidance on the initial evaluation of an infant or an adolescent with a suspected disorder of sex development (Revised 2015). Clin Endocrinol (Oxf). 2016; 84:771–88.

15. Bin-Abbas B, Conte FA, Grumbach MM, Kaplan SL. Congenital hypogonadotropic hypogonadism and micropenis: effect of testosterone treatment on adult penile size why sex reversal is not indicated. J Pediatr. 1999; 134:579–83.

16. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, et al. The ensembl variant effect predictor. Genome Biol. 2016; 17:122.

17. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the american college of medical genetics and genomics and the association for molecular pathology. Genet Med. 2015; 17:405–24.

18. Battaglia A, Hoyme HE, Dallapiccola B, Zackai E, Hudgins L, McDonald-McGinn D, et al. Further delineation of deletion 1p36 syndrome in 60 patients: a recognizable phenotype and common cause of developmental delay and mental retardation. Pediatrics. 2008; 121:404–10.

19. Erdogan S, Kara C, Ucakturk A, Aydin M. Etiological classification and clinical assessment of children and adolescents with disorders of sex development. J Clin Res Pediatr Endocrinol. 2011; 3:77–83.

20. Grouthier V, Bachelot A. Long-term outcomes in non-CAH 46,XX DSD. Front Endocrinol (Lausanne). 2024; 15:1372887.

21. O'Connell MA, Atlas G, Ayers K, Sinclair A. Establishing a molecular genetic diagnosis in children with differences of sex development: a clinical approach. Horm Res Paediatr. 2023; 96:128–43.

22. Kim HI, Lee I, Kim SH, Lee YS, Han SW, Yun BH. Ovotesticular disorder of sex development in Korean children: a single-center analysis over a 30-year period. J Pediatr Adolesc Gynecol. 2021; 34:626–30.

23. Ganie Y, Aldous C, Balakrishna Y, Wiersma R. The spectrum of ovotesticular disorders of sex development in South Africa: a single-centre experience. Horm Res Paediatr. 2017; 87:307–14.

24. Ono M, Harley VR. Disorders of sex development: new genes, new concepts. Nat Rev Endocrinol. 2013; 9:79–91.

25. Baetens D, Stoop H, Peelman F, Todeschini AL, Rosseel T, Coppieters F, et al. NR5A1 is a novel disease gene for 46,XX testicular and ovotesticular disorders of sex development. Genet Med. 2017; 19:367–76.

26. Bashamboo A, Donohoue PA, Vilain E, Rojo S, Calvel P, Seneviratne SN, et al. A recurrent p.Arg92Trp variant in steroidogenic factor-1 (NR5A1) can act as a molecular switch in human sex development. Hum Mol Genet. 2016; 25:3446–53.

27. Eozenou C, Gonen N, Touzon MS, Jorgensen A, Yatsenko SA, Fusee L, et al. Testis formation in XX individuals resulting from novel pathogenic variants in Wilms' tumor 1 (WT1) gene. Proc Natl Acad Sci U S A. 2020; 117:13680–8.

28. Hadjiathanasiou CG, Brauner R, Lortat-Jacob S, Nivot S, Jaubert F, Fellous M, et al. True hermaphroditism: genetic variants and clinical management. J Pediatr. 1994; 125:738–44.

29. Jaruratanasirikul S, Engchaun V. Management of children with disorders of sex development: 20-year experience in southern Thailand. World J Pediatr. 2014; 10:168–74.

30. Ahmed SF, Khwaja O, Hughes IA. The role of a clinical score in the assessment of ambiguous genitalia. BJU Int. 2000; 85:120–4.

31. Gurbuz F, Alkan M, Celik G, Bisgin A, Cekin N, Unal I, et al. Gender identity and assignment recommendations in disorders of sex development patients: 20 years' experience and challenges. J Clin Res Pediatr Endocrinol. 2020; 12:347–57.

32. van der Straaten S, Springer A, Zecic A, Hebenstreit D, Tonnhofer U, Gawlik A, et al. The external genitalia score (EGS): a European Multicenter Validation Study. J Clin Endocrinol Metab. 2020; 105:dgz142.

33. Martin CL, Ruble DN, Szkrybalo J. Cognitive theories of early gender development. Psychol Bull. 2002; 128:903–33.

34. Costanzo M, Touzon MS, Marino R, Guercio G, Ramirez P, Mattone MC, et al. Gonadal tumor development in 46,XX disorders of gonadal development. Eur J Endocrinol. 2022; 187:451–62.

35. Verkauskas G, Jaubert F, Lortat-Jacob S, Malan V, Thibaud E, Nihoul-Fékété C. The long-term followup of 33 cases of true hermaphroditism: a 40-year experience with conservative gonadal surgery. J Urol. 2007; 177:726–31; discussion 731.